Aim of the experiment:
To undertake a quantitative assessment of the signalling differences between iPSCs expressing either wild-type *PIK3CA* or *PIK3CA*-H1047R from one or both endogenous alleles, following 24-hour vehicle treatment or treatment with the PIK3CA-specfic inhibitor BYL719. Using RPPA with antibodies against components of the PI3K and MAPK signalling pathway, as well as several other targets of relevance to iPSCs biology.
Model system: human iPSCs expressing either wild-type PIK3CA, or PIK3CA-H1047R from either one or both endogenous alleles. Collected following 24 hour treatment with either DMSO or 100 nM BYL719; with 1h growth factor removal prior to collection to ensure that subtle signalling differences are not saturated.
RPPA technical procedure performed by Edinburgh Cancer Research Centre (Kenneth Macleod)
See the Powerpoint in the “Raw” directory for additional technical details and flagged data.
For additional information on the remaining files in this folder, see the accompanying RNotebook. If opened within the accompanying RProject alongside the .RData file, the remaining files contained within this folder should be sufficient to reproduce the results presented in the associated publication, in addition to more in-depth QC results.
